ATAGI update following weekly COVID-19 meeting – 9 February 2022

An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 9 February 2022.

Date published:
General public

Latest recommendation updates:

  • ATAGI provided advice on defining ‘up-to-date’ status.

Recent ATAGI considerations

On Wednesday 9 February 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation.  As of 8 February 2022, over 51 million doses of COVID-19 vaccines have been administered in Australia. ATAGI encourages anyone aged 16 years and over to receive a booster dose as soon as they are eligible.

ATAGI Advice on defining ‘up-to-date’ status

ATAGI recognises the importance of providing guidance on a person’s ‘up-to-date' vaccination status from the clinical benefit perspective and also serving as a basis for policies for the public health management of the COVID-19 pandemic in a domestic context.

ATAGI has issued new advice defining up-to-date vaccination status as defined by the number and timing of appropriate COVID-19 vaccine doses recommended for and received by an individual, according to their age and other factors.

ATAGI notes that the concept of being up-to-date with vaccination may be different to what has been required to be ’fully vaccinated’, which is a term that has been used in the context of public health orders or mandates in various settings, including border control, quarantine, workplaces (e.g. aged care, health care), and in other select settings. These applications may involve legal and policy implications and are not within the remit of ATAGI but should be considered in the implementation of this advice by governments and/or private entities as appropriate.

The ATAGI COVID-19 up-to-date vaccination status recommendations will be utilised by the Australian Immunisation Register to assist in determining whether an individual has had the recommended vaccine doses.

Full details of ATAGI’s advice is available here.

Upcoming ATAGI considerations

ATAGI is continuing to monitor evidence on the effectiveness of vaccine boosters and national vaccination coverage rates.

COVID-19 vaccine safety

The Therapeutic Goods Administration (TGA) Weekly Report provides a detailed breakdown of adverse events following immunisation.

Duration of observation after COVID-19 vaccination

ATAGI reaffirms its recommendation that individuals who receive a COVID-19 vaccine, regardless of the vaccine brand and the dose number, should be observed for at least 15 minutes following vaccine administration at the clinic site, in accordance with the current recommendations in the Australian Immunisation Handbook.

Some people with specific allergies as specified in the Precautions section of the current ATAGI Clinical guidance for COVID-19 vaccine providers will require observation for at least 30 minutes following administration of a COVID-19 vaccine dose.

Resources and recent statements

ATAGI recommends review of the following key resources:

More information can be found on the Department of Health website, with resources for both providers and patients.

Help us improve

If you would like a response please use the enquiries form instead.